A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer
Ursula A. Matulonis,Bradley J. Monk,Angeles Alvarez Secord,Melissa A. Geller,David Miller,N.G. Cloven,Gini F. Fleming,A.E. Wahner Hendrickson,Masoud Azodi,Paul DiSilvestro,Amit M. Oza,Mihaela C. Cristea,Jonathan S. Berek,John K. Chan,Y. Li,Katarina Luptakova,Sebastien Hazard,Kathleen N. Moore +17 more
Journal ArticleDOI
Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
Ainhoa Madariaga,Ainhoa Madariaga,Swati Garg,Jeff Bruce,Sakinah Thiryayi,Sakinah Thiryayi,Victoria Mandilaras,Victoria Mandilaras,Prisni Rath,Amit M. Oza,Amit M. Oza,Neesha C. Dhani,Neesha C. Dhani,David W. Cescon,David W. Cescon,Yeh Chen Lee,Yeh Chen Lee,Eric Chen,Eric Chen,Lisa Wang,Lisa Wang,Blaise A. Clarke,Blaise A. Clarke,Stephanie Lheureux,Stephanie Lheureux +24 more
TL;DR: Intrinsic tumor pathways may impact outcome with weekly paclitaxel monotherapy and further investigations are required.
Journal ArticleDOI
Angiogenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial
Anne M. Schultheis,D. Y. Yang,A. A. Garcia,Rebecca L. Morgan,David R. Gandara,Sidney A. Scudder,Amit M. Oza,H. Hirte,Gini F. Fleming,L. Roman,H. J. Lenz +10 more
TL;DR: The data suggest for the first time, that IL-8 may be a potential molecular predictor of response to Bevacizumab based chemotherapy and demonstrate that both VEGF 936 and the AM 3' dinucleotide repeat polymorphisms are potential molecular markers for time to tumor progression.
Journal ArticleDOI
SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.
Ignace Vergote,Jose Alejandro Perez-Fidalgo,Erika Hamilton,Toon Van Gorp,Giorgio Valabrega,Annouschka Laenen,Amit M. Oza,Tally Levy,David Cibula,Jalid Sehouli,Eva Guerra,Hye Sook Chon,Alice Bergamini,Ignacio A. Romero,Dayana Michel,Jatin J. Shah,Bradley J. Monk,Brian M. Slomovitz,Mansoor Raza Mirza,Vicky Makker +19 more
TL;DR: This study is a multicenter, double-blind, placebo-controlled, randomized phase 3 study to evaluate the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent EC following platinum-based chemotherapy.
Journal ArticleDOI
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Marina Bagnoli,Tingyan Shi,Charlie Gourley,Paul Speiser,Alexander Reuss,Hans W. Nijman,Carien L. Creutzberg,Suzy Scholl,Anastassia Negrouk,Mark F. Brady,Kosei Hasegawa,Katsutoshi Oda,Iain A. McNeish,Elise C. Kohn,Amit M. Oza,Helen Mackay,David Millan,Katherine Bennett,Clare L. Scott,Delia Mezzanzanica +19 more
TL;DR: To maximize patients’ benefit, translational studies should be integral to clinical trial design with standardization and optimization of procedures including a harmonization program of Standard Operating Procedures.